Citius Pharmaceuticals In... (CTXR)
NASDAQ: CTXR
· Real-Time Price · USD
1.33
-0.07 (-5.00%)
At close: Aug 29, 2025, 3:59 PM
1.33
0.01%
After-hours: Aug 29, 2025, 07:30 PM EDT
Citius Pharmaceuticals Cash Flow Statement
Financials in USD. Fiscal
year is
October - September.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
Net Income | -11.51M | -10.28M | -11.08M | -10.57M | -8.54M | -9.23M | -9.94M | -8.48M | -10.53M | -3.59M | -7.99M | -8.86M | -7.56M | -9.23M | -4.96M | -5.82M | -4.12M | -8.15M |
Depreciation & Amortization | 56.01K | 54.84K | 53.69K | 52.85K | 52.07K | 51.01K | 49.97K | 49.02K | 48.14K | 47.19K | 46.25K | 45.35K | 44.47K | 43.61K | 42.77K | 41.68K | 40.59K | 39.82K |
Stock-Based Compensation | 2.7M | 2.52M | 2.64M | 3.06M | 3.08M | 3.06M | 3.08M | 1.17M | 1.17M | 1.2M | 976.67K | 1M | 1.02M | 904.6K | 461.87K | 373.57K | 342.96K | 276.58K |
Other Working Capital | 2.9M | 6.39M | -938.42K | -156.42K | -2.64M | 46.62K | 26.14K | -2.82M | 25.28K | -3M | 480.13K | 117.18K | -3.26M | 3.02M | -890.45K | 363.46K | -749.12K | -862.02K |
Other Non-Cash Items | n/a | n/a | 1.00 | 109.95K | 3.26M | 76.15K | 3.33M | 918.07K | 102K | 923.25K | 104.32K | 1.11M | 178K | 95.88K | -166.56K | 235.15K | 68K | -872.06K |
Deferred Income Tax | 264.24K | 264.24K | 144K | 144K | 144K | 144K | 144K | 144K | 144K | 144K | 576K | -1.11M | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | 3.95M | 2.71M | 2.33M | -1.16M | -2.61M | -233.46K | -126.19K | -2.47M | 1.21M | -2.62M | -45.01K | 102.57K | -3.35M | 3.53M | -968.02K | 585.25K | -600.42K | -1.73M |
Operating Cash Flow | -4.54M | -4.73M | -5.91M | -8.37M | -7.79M | -6.14M | -6.8M | -9.58M | -7.85M | -4.82M | -6.33M | -7.71M | -9.67M | -4.65M | -5.59M | -4.82M | -4.27M | -9.56M |
Capital Expenditures | -4 | n/a | n/a | -4 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -40M | -6.94K | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | -5M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -40M | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | -5M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -40M | -6.94K | n/a | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | n/a | -3.83M | 13.72M | n/a | n/a | -687 | 13.8M | 31.27K | n/a | n/a | n/a | n/a | n/a | -31.04M | 16.8M | 14.24M | n/a |
Financial Cash Flow | 3.47M | 2.57M | -3.75M | 13.72M | n/a | n/a | -687 | 13.8M | 31.27K | n/a | n/a | n/a | n/a | n/a | -120.47M | 16.8M | 103.67M | 500.00 |
Net Cash Flow | -1.07M | -2.15M | -14.66M | 5.35M | -7.79M | -6.14M | -6.8M | 4.22M | -7.82M | -4.82M | -6.33M | -7.71M | -9.67M | -4.65M | -45.59M | 11.97M | 99.4M | -9.56M |
Free Cash Flow | -4.54M | -4.73M | -5.91M | -8.37M | -7.79M | -6.14M | -6.8M | -9.58M | -7.85M | -4.82M | -6.33M | -7.71M | -9.67M | -4.65M | -45.59M | -4.83M | -4.27M | -9.56M |